The new medical practice environment. Internists' view of the future

1989 ◽  
Vol 149 (8) ◽  
pp. 1745-1749 ◽  
Author(s):  
C. O. Hershey
The Lancet ◽  
1962 ◽  
Vol 280 (7250) ◽  
pp. 257-258 ◽  
Author(s):  
D CROMBIE
Keyword(s):  

The Lancet ◽  
1928 ◽  
Vol 211 (5446) ◽  
pp. 67-69
Author(s):  
Somerville Hastings
Keyword(s):  

1967 ◽  
Vol 5 (25) ◽  
pp. 97-99

Preparations from Cannabis sativa, the hemp plant, were omitted from the B.P. in 1932, and from the B.P.C. in 1949. Today, they are scarcely used in medical practice, though manufacture of a tincture of cannabis is still licenced (and one or two practitioners are known to prescribe it from time to time for psychiatric or psychosomatic disorders1). Cannabis and preparations derived from it are controlled by the Dangerous Drugs Act, yet they are more widely and increasingly used in this country and in America than any other illicit drug. But this is not the only reason for discussing their effects in the Drug and Therapeutics Bulletin: the future use of some synthetic analogues and derivatives seems probable as analgesics, antidepressants and antihypertensives.2


PEDIATRICS ◽  
1972 ◽  
Vol 49 (4) ◽  
pp. 636-636
Author(s):  
Norman Lewak

In their "Guidelines for the Diagnosis of Streptococcal Infection" (Pediatrics, 48:573, 1971), Honikman and Massell did not specify whether the guidelines should vary by geographic location. Taking into consideration the economic factors mentioned by the authors, should the same guidelines apply to different areas of the country which have markedly different incidences of rheumatic fever? We are all aware that the public is (rightfully) taking a close look at the quality of medical practice. Practice audits appear to be a certainty in the future.


Sign in / Sign up

Export Citation Format

Share Document